Sanofi (NASDAQ:SNY) Stock Has Average Price Target of $49.50 According to Brokerages

Sanofi (NASDAQ:SNY) has earned a consensus recommendation of “Hold” from the twenty-one analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $49.50.

SNY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. Wall Street Zen cut Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Sanford C. Bernstein reiterated a “buy” rating on shares of Sanofi in a report on Monday, August 3rd. Morgan Stanley set a $49.00 target price on Sanofi in a research report on Wednesday, July 8th. Finally, Royal Bank Of Canada initiated coverage on Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating on the stock.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently added to or reduced their stakes in SNY. Focus Financial Network Inc. grew its position in shares of Sanofi by 49.9% in the 3rd quarter. Focus Financial Network Inc. now owns 7,950 shares of the company’s stock valued at $328,000 after buying an additional 2,648 shares during the last quarter. Avior Wealth Management LLC raised its stake in Sanofi by 5.2% during the 3rd quarter. Avior Wealth Management LLC now owns 6,412 shares of the company’s stock worth $264,000 after acquiring an additional 319 shares in the last quarter. Sound Income Strategies LLC raised its stake in Sanofi by 1.6% during the 3rd quarter. Sound Income Strategies LLC now owns 92,404 shares of the company’s stock worth $3,717,000 after acquiring an additional 1,447 shares in the last quarter. GAMMA Investing LLC lifted its position in Sanofi by 32.3% in the third quarter. GAMMA Investing LLC now owns 5,675 shares of the company’s stock valued at $234,000 after acquiring an additional 1,386 shares during the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in Sanofi by 10.8% in the third quarter. Valeo Financial Advisors LLC now owns 6,346 shares of the company’s stock valued at $262,000 after acquiring an additional 616 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY opened at $40.61 on Friday. Sanofi has a twelve month low of $39.07 and a twelve month high of $52.68. The firm’s fifty day simple moving average is $42.68 and its 200-day simple moving average is $43.79. The firm has a market capitalization of $98.46 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 1.24 and a beta of 0.33. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. Sanofi’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period last year, the firm posted $3.24 earnings per share. Equities analysts forecast that Sanofi will post 5.00 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.